Market research
ALNA Allena Pharmaceuticals Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 9M
- P/E ratio
- Not available
- Analyst target
- 4
- Dividend yield
- 0.0%
- Beta
- 1.15
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US0181191075
- Market cap
- 9M
- P/E ratio
- Not available
- Analyst target
- 4
- Dividend yield
- 0.0%
- Beta
- 1.15
About
About Allena Pharmaceuticals Inc
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ALNA discussion.
5 years, 4 months ago
Allena Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 16.0% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Allena Pharmaceuticals, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 9.7% to $-10M since the same quarter in the previous year.
Finally, its free cash flow grew by 29.3% to $-9M since the same quarter in the previous year.
Based on the above factors, Allena Pharmaceuticals, Inc gets an overall score of 3/5.